论文部分内容阅读
近年来,随着病理学和肿瘤个性化治疗的迅速发展,免疫组化技术的应用越来越受到大家的重视,正逐渐从病理诊断的辅助技术转变为病理诊断的主要技术手段之一,为病理诊断、临床个性化治疗及疾病预后判断[1]提供了重要的参考依据,已成为临床病理工作中不可或缺的重要角色。但是,随着这种技术的广泛应用及多种检测方法的建立和大量新抗体的不断涌现,免疫组化技术的标准化及质量控制问题也日益突出,为此,同行们也进行了一系列的探索,取得了许
In recent years, with the rapid development of pathology and personalized cancer treatment, the application of immunohistochemistry has drawn more and more attention from people, and is gradually shifting from the auxiliary technique of pathological diagnosis to one of the main technical means of pathological diagnosis. Pathological diagnosis, personalized clinical treatment and disease prognosis [1] provides an important reference, has become an indispensable role in clinical pathology. However, with the wide application of this technology and the establishment of various detection methods and the continuous emergence of a large number of new antibodies, the problems of standardization and quality control of immunohistochemical techniques have also become increasingly prominent. For this reason, colleagues also conducted a series of Explore, made a promise